Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurses perspective

Supportive Care in Cancer, 05/08/2012

The considerable side effects of high–dose IFN alfa–2b (HDI) can be managed using established strategies. Oncology nurses play a significant role in the management of patients with melanoma receiving adjuvant HDI, and their prompt recognition of side effects, together with an understanding of effective pharmacological and nonpharmacological interventions, will improve patient comfort; this has the potential to positively influence treatment adherence and completion of the recommended treatment course.

Print Article Summary Cat 2 CME Report